Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US03843E1047
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00L9HP0Z0
AQST
Aquestive Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Aquestive Therapeutics Inc
ISIN
US03843E1047
TICKER
AQST
MIC
XNAS
REUTERS
AQST.OQ
BLOOMBERG
AQST US
Mo., 27.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If yo...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 23, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aquestive Therapeutics
US03843E1047

Important Information Regarding Section 20(a) Individual Liability ClaimsNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual defendant in a pending securities c...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 22.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 22, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates in...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aquestive Therapeutics
US03843E1047

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innova...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Sa., 18.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Aquestive Therapeutics
US03843E1047

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA? NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through January 8, 2026. Shareholders who lost money on AQST stock may find out if you...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If yo...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 15, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP:Do you, or did you, own shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST)?Did you purchase your shares between June 16, 2025 and January 8, 2026, inclusive?Did you lose money in your investment in Aquestive Therapeutics, Inc.?Do you want to discuss your rights?Bernst...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 11.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The Aques...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encour...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates incl...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Aquestive Therapeutics
Charts & Research Termsheets Terminal
Permalink